Inicio › Colitis ulcerativa › Georgia
Ensayos clínicos de Colitis ulcerativa en Georgia
13 estudios sobre Colitis ulcerativa buscan participantes en Georgia.
Ciudades en Georgia
Texto oficial del estudio (inglés)
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- Gastroenterology Associates of Central Georgia ( Site 1060), Macon
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 12 nov 2026 · NCT07463183A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 4 nov 2026 · NCT07483073A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Emory University, Atlanta
- Children's Center for Digestive Healthcare, Atlanta
ReclutandoFase 3
Edades de 3 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06663332A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Atlanta Gastroenterology Specialists, Suwanee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07577856A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Digestive Healthcare of Georgia, Atlanta
- AGA GA Research LLC, Atlanta
ReclutandoFase 4
Edades de 18 a 80 · Todos los sexos · Actualizado el 28 oct 2026 · NCT06581328Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Associates of Central Georgia /ID# 280464, Macon
- Gastroenterology Consultants - Roswell /ID# 281235, Roswell
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 27 oct 2026 · NCT07697456A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- Childrens Center For Digestive Health Care /ID# 273228, Atlanta
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 27 oct 2026 · NCT07071519An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Atlanta Gastroenterology Associates - Site Number: 8400109, Atlanta
- M3 Wake Research - Atlanta - Site Number: 8400028, Sandy Springs
- EBGS Clinical Research Center, LLC - Site Number: 8400037, Snellville
- y 1 más
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 23 oct 2026 · NCT07184996A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Atlanta Gastroenterology Associates-Site Number: 8400109, Atlanta
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 16 oct 2026 · NCT07185009A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Emory University School of Medicine, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
ReclutandoFase 3
Edades de 2 a 19 · Todos los sexos · Actualizado el 7 oct 2026 · NCT04844606Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
- Gastroenterology Consultants, P.C., Roswell
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 21 sept 2026 · NCT07513181A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
ReclutandoFase 3
Edades de 2 en adelante · Todos los sexos · Actualizado el 7 may 2026 · NCT05442567A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Atlanta
- Mirador Therapeutics Selected Site, Snellville
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 12 mar 2026 · NCT07113522De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.